Holen Sie sich die Stockscreener-App
0.8221
0.87%
-0.0072
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
SKYE: All proposals passed, directors elected, and no stakeholder questions were raised - TradingView
SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Australia
Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1 - marketscreener.com
Skye Bioscience gets approval to open second cohort in study - Investing.com
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - The Manila Times
Obesity drug trial sees no serious side effects as dose moves higher - Stock Titan
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87 - MSN
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity - The Globe and Mail
[8-K] Skye Bioscience, Inc. Reports Material Event - Stock Titan
SKYE Should I Buy - Intellectia AI
Nimacimab obesity trial progresses as Skye Bioscience initiates CBeyond study Part C - Traders Union
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - Moomoo
Skye Bioscience 4Q Loss/Shr 36c >SKYE - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
UPDATESkye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026 - Quiver Quantitative
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire
Press Release: UPDATE -- Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - Moomoo
Skye Bioscience stock price target cut to $6 by Piper Sandler on cash runway - Investing.com
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Skye obesity drug combo saw 22.3% weight loss at 52 weeks - Stock Titan
SKYE Advances CBeyond Program toward Phase 2b Trials - GuruFocus
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
SKYE: Promising Phase 2a combo results, but Q1 net loss and funding risks threaten future operations - TradingView
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Skye Bioscience, Inc. Quarterly Earnings Report - Stock Titan
Number of shareholders of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Skye weight-loss trial combo hits 22% mean loss at 52 weeks - Stock Titan
Biotech Overhyping Obesity Drug Hurt Investors, Suit Says - Law360
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
SKYE Technical Analysis | Trend, Signals & Chart Patterns | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) CFO John P. Sharp files initial Form 3 - Stock Titan
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Investigation Alert: Long-Term Investors who lost money with - openPR.com
Skye Bioscience (SKYE) Stock: Continuation Signals (At Highs) 2026-04-22Top Analyst Picks - Xã Vĩnh Công
[ARS] Skye Bioscience, Inc. SEC Filing - Stock Titan
Skye Bioscience (SKYE) seeks share increase and votes on pay at 2026 meeting - Stock Titan
Ideas Watch: What is the next catalyst for Skye Bioscience IncWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Profit Review: Is Skye Bioscience Inc in a bullish channel2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Guidance Update: Can Skye Bioscience Inc weather a recessionTake Profit & AI Powered Market Trend Analysis - baoquankhu1.vn
Skye Bioscience, Inc. advances nimacimab development targeting higher-dose safety and practical dosing options - Traders Union
Skye CEO to outline obesity drug approach at Boston GLP-1 summit - Stock Titan
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit - GlobeNewswire
SKYE BIOSCIENCE, INC. 8-K/A SEC Filing: Company Information, Address, and Regulatory Details (March 31, 2026) - Minichart
Skye Bioscience (NASDAQ: SKYE) reports 52‑week nimacimab results, seeks 3x share authorization - Stock Titan
Skye Bioscience (SKYE) seeks to triple authorized shares; nimacimab posts 22.3% weight loss signal - Stock Titan
Skye Bioscience (SKYE) fixes share count for repriced stock options - Stock Titan
Will Skye Bioscience Inc outperform the market in YEARMarket Trend Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
SKYE SEC FilingsSkye Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Skye Bioscience Signs Master Services Agreement With Lohman & Associates for Finance and Accounting Consulting - Minichart
Earnings Miss: Whats the outlook for Skye Bioscience Incs sectorWeekly Investment Recap & High Accuracy Swing Trade Signals - baoquankhu1.vn
Skye Bioscience Treats First Patient in Nimacimab Dose Study - The Clinical Trial Vanguard
Skye Bioscience reduces employee stock option exercise prices and appoints new CFO By Investing.com - Investing.com South Africa
Skye Bioscience reduces employee stock option exercise prices and appoints new CFO - Investing.com Australia
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):